• 关于我们
  • 律师
  • 执业领域
    • 行业
        • 技术、媒体和通信 (TMC)
        • 国际私人财富
        • 房地产、基础设施和能源
        • 生命科学和医疗保健
        • 航空航天与国防
        • 自动化
        • 商业和专业服务
        • 化学制品
        • 消费与零售
        • 金融机构和保险
        • 酒店与休闲
        • 物流与运输
        • 制造业与工业
        • 公共服务和教育
    • 法律服务
        • Artificial intelligence
        • 银行与金融
        • 品牌和广告
        • 商业和消费者合同
        • 竞争、欧盟与贸易
        • 版权和媒体
        • 公司犯罪与合规
        • 国际企业并购与资本市场
        • 数据和网络
        • 纠纷和调查
        • 就业、养老金和流动性
        • 环境规划与监管
        • 环境、社会和公司治理 (ESG)
        • 信息技术
        • Multi-service
        • 专利与创新
        • 私人客户
        • 私募股权
        • 项目、能源和基础设施
        • 房地产与建筑
        • Regulation
        • 重组和破产
        • 税务
        • 风险投资
  • 法域
    • 欧洲
        • 位置
        • 奥地利
        • 比利时
        • 捷克共和国
        • 法国
        • 德国
        • 匈牙利
        • Italy
        • 荷兰
        • 波兰
        • Portugal
        • 爱尔兰共和国
        • 斯洛伐克
        • Spain
        • 英国
        • 乌克兰
          团体
        • CEE Turkish Desk
        • 法国德国团队
        • 办公室
    • 中东和非洲
        • 位置
        • 中东
        • 阿联酋
          团体
        • 非洲团队
        • 以色列团队
        • 办公室
    • 美洲
        • 位置
        • Latin America
        • 美国
          团体
        • 巴西团队
        • 办公室
    • 亚洲
        • 位置
        • 亚洲
        • 中国
        • 韩国
          团体
        • 印度团队
        • 日本团队
        • 办公室
  • 新闻和观点
    • 观点
        • 热点话题
        • Artificial intelligence
        • Data Centre Expertise
        • The EU Whistleblower Directive
        • German Supply Chain Act
        • Unified Patent Court
          Content hub
        • Global Data Hub
        • Interface: 技术、知识产权和媒体法
        • Podcasts
        • Synapse
        • 浏览所有观点
    • 活动
        • 亲自
        • 在线的
        • Browse All Events
    • 新闻
        • 媒体中心
        • 工作亮点
        • 律所新闻
        • 查看全部
  • 职业发展
  • ZH
    • English
    • 中文(简体)
    • Français
    • Deutsch
  • Home
  • People
  • Matthew Royle
Matthew Royle, Ph.D.
Matthew Royle, Ph.D.

Matthew Royle, Ph.D.

合伙人

  • 伦敦 英国
+44 20 7300 4608
vCard
发送电子邮件给我 Call me
奖励

Managing Intellectual Property – IP Stars 2024

Patent star

Scroll to featured award

Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice.

Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly.

A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaeutical, biotech and life sciences sectors.  He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.

专长

执业领域和服务团队

专利与创新
纠纷和调查
医疗监管
知识产权纠纷
技术纠纷
生命科学监管咨询
专利与专有技术争议解决

行业

酒店与休闲
生物技术
医疗器械
制药

Patent Perspective Quick Listens

A UPC and European patent litigation podcast.

Listen now

CV

Since 2015 Partner, Taylor Wessing
2011 - 2015 Senior Associate, Taylor Wessing
2006 - 2011 Associate, Taylor Wessing
2004 - 2006 Trainee solicitor, Taylor Wessing
2007 Diploma in Intellectual Property Law, Bristol University, UK
2006 Admitted to the Bar, England and Wales
2002 PhD, Molecular Immunology, University of Cambridge, UK
1998 Degree, Medical Microbiology, University of Edinburgh, UK

职业发展

Since 2015 Partner, Taylor Wessing
2011 - 2015 Senior Associate, Taylor Wessing
2006 - 2011 Associate, Taylor Wessing
2004 - 2006 Trainee solicitor, Taylor Wessing

教育

2007 Diploma in Intellectual Property Law, Bristol University, UK
2006 Admitted to the Bar, England and Wales
2002 PhD, Molecular Immunology, University of Cambridge, UK
1998 Degree, Medical Microbiology, University of Edinburgh, UK

Publications

EU Guidance on biosimilar MAbs - what took so long?, Scrip Regulatory Affairs, pp 10-12, 17, July 2012
Neurim - EU Advocate General argues that supplementary protection certificates should be allowed for usage patents, Scrip Regulatory Affairs, p 5, 22, May 2012

会员资格和附属关系

Associate member of CIPA

语言

English

奖励

Managing Intellectual Property – IP Stars 2024

Featured

Patent star

Chambers and Partners UK 2023

Life Sciences (IP/patent litigation) - Band 2: Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. Prior to his legal career he undertook a doctorate in medical microbiology. "A well-respected litigator." "Matthew Royle is clearly very clever and good at managing challenging situations."

Chambers and Partners UK 2023

Intellectual Property (patent litigation) - Band 3: Matthew Royle acts for pharmaceutical companies in patent litigation and also advises them on SPCs and regulation. He has taken a number of cases to the UK Supreme Court.

Chambers UK 2022

Life Sciences - IP/Patent Litigation: "A good litigator, with a good knowledge of the life sciences sector. He has a particular focus on the generics side."

Intellectual Property - Patent Litigation

"The Impact Case of the Year" for Actavis v ICOS case, where we acted for Mylan in relation to litigation on two patents relating to Lilly's blockbuster drug Cialis® (tadalafil).

Leading individual - Life Sciences: IP/Patent (band 3) and IP: patent litigation (band 4).

Leading individual - Life Sciences: IP/Patent litigation (Band 3): Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. A source says: "He is a very good patent litigator – sensible, pragmatic and a pleasure to work with."

Leading individual - Intellectual Property: Patent litigation (Band 4): Matthew Royle acts for pharmaceuticals companies in patent litigation and also advises them on SPCs and regulation. A source says: "He is a very good patent litigator - sensible, pragmatic and a pleasure to work with."

Leading individual - TMT: Pharmaceuticals and Biotech

Leading individual: litigation (Bronze): Matthew Royle is a canny and highly trained harvester of SPC extensions – a “well-known, longstanding presence in intellectual property”.

Leading individual: Patents

Patent star

For Pregabalin Supreme Court case

Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a patent litigator and pharmaceuticals regulation expert with an academic background in medical microbiology. A source says: "He is a real hands-on partner in a lot of major cases."

Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is known for representing generic pharmaceutical manufacturers in high-stakes patent litigation such as patent revocation actions and disputes concerning contested SPCs. A source says: "He is a real hands-on partner in a lot of major cases."

Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a rising life sciences patent litigator whose recent work has involved questions of secondary medical uses, dosage regimes and SPCs. A market commentator says he is "very strong on the science."

Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is distinguished for his representation of generic pharmaceutical manufacturers in high-value patent revocation actions and cases concerning SPCs. Sources note that he is "very strong on the science."

‘Rising star’ in litigation

Experience

A life sciences company

A life sciences company on market formation dates in relation to orphan medicinal products.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on the validity of and expiry of supplementary protection certificates for a product launch.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on an EPO opposition in relation to a pharmaceutical.

Matthew Royle, Ph.D.

A company dealing with commercialisation arrangements for university discoveries

A company dealing with commercialisation arrangements for university discoveries on a dispute between co-inventors in relation to a patent.

Matthew Royle, Ph.D.

A life sciences company

A life sciences company on data exclusivity in relation to a combination product in the context of a sale of that product.

Matthew Royle, Ph.D.

最新新闻和观点

View Matthew's insights
点击此处了解更多
专利与创新

Episode 5: How is substantive law developing in the Unified Patent Court (UPC)?

2025年3月17日

作者

Glass.Mapper.Sc.Fields.Image?.Alt
UPC

Good news for patent proprietors: the CoA's decision on the requirements for withdrawing an opt-out

2024年11月25日
In-depth analysis

作者

点击此处了解更多
Glass.Mapper.Sc.Fields.Image?.Alt
专利与创新

What is the language of the UPC?

2024年7月31日
In-depth analysis

作者

点击此处了解更多
View Matthew's insights

Related news & insights

酒店与休闲

Advising SENISCA on its partnership with L'Oréal

2025年7月4日

作者 Colin McCall 以及 Charlie Adams

点击此处了解更多
ESG
环境、社会和公司治理 (ESG)

Green Patents and ESG Innovation: The Role of the European Patent Framework

2025年7月3日
Briefing

作者 Laura Coucke 以及 Adam Lybaert

点击此处了解更多

The Critical Medicines Act: A New Pillar of European Pharmaceutical Resilience

2025年6月26日
Briefing

作者 Alina Krukover

点击此处了解更多
酒店与休闲

Life Sciences as a Security-Relevant Sector: Is Innovation at Risk under European and German FDI Control?

2025年6月26日
Briefing

作者 Dr. Carolin Roßkothen, LL.M.

点击此处了解更多
酒店与休闲

China’s Rare Earth Export Controls: Implications for European Life Sciences Companies

2025年6月26日
Briefing

作者 Dr. Amir-Said Ghassabeh

点击此处了解更多
酒店与休闲

Corporate Venturing in Life Sciences: Making Partnerships Truly Strategic

2025年6月26日
Quick read
点击此处了解更多
酒店与休闲

Higher Regional Court of Frankfurt am Main on online referral of doctors for the prescription of medical cannabis

2025年6月24日
In-depth analysis

作者 Dr. Daniel Tietjen 以及 Ennio Schwind, LL.M. Eur.

点击此处了解更多
酒店与休闲

Request for a preliminary ruling by the BGH to the CJEU on the scope of the duty of care of medical device distributors

2025年6月23日
In-depth analysis

作者 Dr. Daniel Tietjen 以及 Daniel Dietrich

点击此处了解更多
酒店与休闲

Appeal proceedings on the admissibility of granting Rx bonuses to a mail-order pharmacy based in the EU

2025年6月23日
Briefing

作者 Dr. Daniel Tietjen 以及 Ennio Schwind, LL.M. Eur.

点击此处了解更多
酒店与休闲

Federal Court of Justice (BGH): Placing medicinal products on the market within the meaning of Section 43 (1) of the German Medicines Act (AMG) when selling pharmacy-only medicines via the Amazon Marketplace

2025年6月23日
In-depth analysis

作者 Dr. Daniel Tietjen 以及 Daniel Dietrich

点击此处了解更多
View all insights

相关人员

英国
Simon Cohen

Simon Cohen

合伙人

伦敦
+44 20 7300 4815
发送电子邮件给我
查看个人资料
Full team

与我会面:

查看所有活动
订阅
  • 关于我们
  • Campaigns and online tools
  • 新闻
  • 律师
  • 执业领域
  • 法域
  • 新闻和观点
  • 活动
  • 媒体中心
  • 联系方式
  • 职业发展
  • 校友
  • 数据保护和隐私政策
  • 网络隐私和 Cookie 政策
  • 监管
  • 有关费用的监管信息
  • 客户投诉程序
  • 使用条款
  • 反奴役宣言
  • 环境
  • 垃圾电子邮件

© Taylor Wessing